© 2018 by BioSight Ltd.

  • LinkedIn Social Icon

News & Events

November 6, 2019, Airport City, Israel

Biosight Announces Data to be Presented at ASH 2019 Annual Meeting 


Results from an ongoing Phase 2b clinical trial of BST-236 (aspacytarabine) for treatment of acute myeloid leukemia (AML), will be presented during an oral session at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.

The data, to be presented by Dr. Jessica K. Altman, Northwestern University, Chicago IL, will include integrated results from a Phase 1/2a study and an ongoing Phase 2b study, of BST-236 as a first-line single-agent treatment for AML patients who are unfit to receive standard intensive chemotherapy.


Oral presentation details:

Title: Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b
Presenter: Jessica K. Altman MD
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies
Session Date: Saturday, December 7, 2019
Session Time: 12:00 PM - 1:30 PM
Presentation Time: 1:00 PM
Room: Orange County Convention Center, Chapin Theater (W320)

June 4, 2019, Airport City, Israel

Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia 


Biosight, a pharmaceutical development company focused on the development of novel oncology therapeutics, announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to BST-236, an investigational novel antimetabolite, for the treatment of acute myeloid leukemia (AML). BST-236 is being developed for the treatment of hematological malignancies and disorders, and is currently in Phase 2b development for front-line treatment of AML.

Read More>>

July 11, 2018, Airport City, Israel


Biosight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia 


BioSight Ltd., a pharmaceutical development company focused on the development of targeted oncology drugs, announced today that it has received the FDA and the Israeli Ministry of Health clearance to launch a Phase 2b clinical trial of BST-236 for treatment of Acute Myeloid Leukemia (AML).

The trial, which will be launched in the upcoming month, will be conducted in 25 medical centers in the US and Israel. BST-236 will be administered as a single agent treatment for newly-diagnosed AML patients, either de novo or secondary to myelodysplastic disorder (MDS) who are unfit for standard chemotherapy due to its severe toxicity. This population is estimated to account for a third to half of the AML patients.

Read More>>


Dec 14, 2017, Airport City, Israel


Biosight Announces Phase I/II Results of Its Cytarabine Pro-Drug BST-236 For Treatment of Acute Leukemia. Results of the Phase I/II Study were Presented at the 59th Annual Meeting of the American Society of Hematology 


Biosight Ltd, a pharmaceutical development company focused on the development of targeted oncology drugs, reports positive final results in a Phase I/II multi-center, open label, dose-escalating study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients. The results, presented at the 59th Annual American Society of Hematology Meeting and Exposition by Dr. Tsila Zuckerman of the Rambam Healthcare Center, demonstrated safety and efficacy of BST-236 as a single agent in treatment of newly-diagnosed acute leukemia patients, unfit for standard induction therapy.

Read More>>

Aug 09, 2017, Airport City, Israel


Biosight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial with BST-236, a Novel Cytarabine Pro-Drug

Biosight Ltd., a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, today announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients. The company expects to report top-line results of the study in the coming months.

Read More>>

Dec 03, 2016, San Diego, CA


BST-236 (Formerly Astarabine), a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

BioSight reports positive interim results of an initial efficacy trial for its Leukemia treatment product.

The company's product, BST-236 (Astarabine), had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) patients unfit for chemotherapy. Results indicate a good response to treatment in the examined group, with minimum side effects. In three out of 15 patients, for whom no treatment could earlier be provided, complete remission was noted for 4-10 months, to date; in two further patients a partial remission was reported for 3-7 months.

Read More>>

May 16, 2016, Karmiel, Israel


Arkin Holdings and Primera Capital Lead an Investment of $13M in Biosight for an Innovative Treatment of Acute Leukemia


Biosight announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of Acute Myeloid Leukemia (AML). 

Read More>>



Dec 7, 2015, Orlando, FL


BST-236 (Formerly Astarabine), a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients


BioSight reported positive interim results in an abstract at the 2015 ASH meeting from a Phase 1/2a clinical study of Astarabine in leukemia patients.

The aim of the study was to evaluate the safety and optimal dose of Astarabine in refractory/relapsed or medically unfit patients with acute leukemia.

In the first three cohorts of nine patients, eight had acute myeloid leukemia (AML), of which four were refractory/relapsed and four were newly diagnosed secondary AML unfit for intensive therapy, while one patient had newly diagnosed relapsed acute lymphoblastic leukemia (ALL).

The study demonstrated that Astarabine was safe and well tolerated, including in patients over 80 years of age, resulting in remission in three of nine patients with acute leukemia.

BioSight is planning a Phase 2 to confirm the encouraging Phase 1/2a results and define the use of Astarabine for patients otherwise unable to receive high doses of cytarabine.



October 26, 2015, Tel Aviv, Israel


Biosight Will Present Interim Results From a Phase 1/2 Clinical Trial of BST-236 (Formerly Astarabine)for Treating Acute Leukemia at the ASH Annual Meeting 2015


Biosight Ltd. announced today it shall report interim results from an ongoing Phase 1/2a clinical study of Astarabine™ in leukemia patients, at the ASH Annual Meeting on December 5-8, 2015 in Orlando, FL. The results will be presented by Dr. Tsila Zuckerman, Head of the Bone Marrow Transplantation Unit at Rambam Healthcare Campus, Technion, Israel.



BIOSIGHT logo .png